Convalescent plasma or hyperimmune immunoglobulin for people with COVID‐19: a living systematic review
Background Convalescent plasma and hyperimmune immunoglobulin may reduce mortality
in patients with viral respiratory diseases, and are currently being investigated in trials as …
in patients with viral respiratory diseases, and are currently being investigated in trials as …
Convalescent plasma for people with COVID‐19: a living systematic review
C Iannizzi, KL Chai, V Piechotta… - Cochrane Database …, 2023 - cochranelibrary.com
Background Convalescent plasma may reduce mortality in patients with viral respiratory
diseases, and is being investigated as a potential therapy for coronavirus disease 2019 …
diseases, and is being investigated as a potential therapy for coronavirus disease 2019 …
High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial
A Alemany, P Millat-Martinez… - The Lancet …, 2022 - thelancet.com
Background Convalescent plasma has been proposed as an early treatment to interrupt the
progression of early COVID-19 to severe disease, but there is little definitive evidence. We …
progression of early COVID-19 to severe disease, but there is little definitive evidence. We …
Fast and accurate surrogate virus neutralization test based on antibody-mediated blocking of the interaction of ACE2 and SARS-CoV-2 spike protein RBD
DE Kolesov, MV Sinegubova, LK Dayanova… - Diagnostics, 2022 - mdpi.com
The humoral response to the SARS-CoV-2 S protein determines the development of
protective immunity against this infection. The standard neutralizing antibodies detection …
protective immunity against this infection. The standard neutralizing antibodies detection …
Benzopyrone, a privileged scaffold in drug discovery: An overview of FDA‐approved drugs and clinical candidates
V Sharma, A Sharma, BN Wadje… - Medicinal Research …, 2024 - Wiley Online Library
Natural products have always served as an important source of drugs for treating various
diseases. Among various privileged natural product scaffolds, the benzopyrone class of …
diseases. Among various privileged natural product scaffolds, the benzopyrone class of …
Inactivation of SARS‐CoV‐2 infectivity in platelet concentrates or plasma following treatment with ultraviolet C light or with methylene blue combined with visible light
Background Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is unlikely to
be a major transfusion‐transmitted pathogen; however, convalescent plasma is a treatment …
be a major transfusion‐transmitted pathogen; however, convalescent plasma is a treatment …
Preservation of anti-SARS-CoV-2 neutralising antibodies in convalescent plasma after pathogen reduction with methylene blue and visible light
L Larrea, E Castro, L Navarro, B Vera… - Blood …, 2021 - pmc.ncbi.nlm.nih.gov
Background COVID-19 convalescent plasma (CCP) is an experimental treatment against
SARS-CoV-2. Although there has so far been no evidence of transmission through …
SARS-CoV-2. Although there has so far been no evidence of transmission through …
Validation of Viral Inactivation Protocols for Therapeutic Blood Products against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)
Therapeutic blood products including convalescent plasma/serum and immunoglobulins
concentrated from convalescent plasma, such as intravenous immunoglobulins or …
concentrated from convalescent plasma, such as intravenous immunoglobulins or …
Efficacy of early transfusion of convalescent plasma with high‐titer SARS‐CoV‐2 neutralizing antibodies in hospitalized patients with COVID‐19
C Sanz, M Nomdedeu, A Pereira, S Sauleda… - …, 2022 - Wiley Online Library
Background Despite most controlled trials have shown no measurable benefit of COVID‐19
convalescent plasma (CCP) in patients with COVID‐19, some studies suggest that early …
convalescent plasma (CCP) in patients with COVID‐19, some studies suggest that early …
Human Intramuscular Hyperimmune Gamma Globulin (hIHGG) Anti-SARS-CoV-2—Characteristics of Intermediates and Final Product
E Lachert, J Lasocka, A Bielawski, E Sulkowska, K Guz… - Viruses, 2022 - mdpi.com
This study aims to characterize the intermediates, and the final product (FP) obtained during
the production of human intramuscular hyperimmune gamma globulin anti-SARS-CoV-2 …
the production of human intramuscular hyperimmune gamma globulin anti-SARS-CoV-2 …